Marlin Global delivered a 4.0% gross portfolio return in April 2026, driven by strong gains in AI-focused tech stocks like Amazon and Alphabet. However, its cautious stance on semiconductors limited upside amid a sector rally.
- 4.0% gross portfolio return in April, trailing benchmark’s 7.8%
- Amazon and Alphabet surged on AI and cloud growth
- Underweight semiconductor exposure detracted amid 40% sector rally
- Healthcare holdings lagged despite resilient procedure volumes
- No portfolio changes; focus remains on long-term growth
April Gains Led by AI-Focused Tech Giants
Marlin Global (NZX:MLN) posted a respectable 4.0% gross portfolio return in April 2026, though it lagged the benchmark S&P Large Mid Cap/Small Cap Index’s 7.8% surge. The standout performers were Amazon (+27%) and Alphabet (+34%), whose earnings beats and aggressive AI investments reignited investor enthusiasm. Amazon’s cloud arm, AWS, accelerated revenue growth, underpinned by proprietary AI chips that have already hit a $20 billion run-rate, showcasing its end-to-end AI capabilities.
Alphabet and Meta also impressed by balancing heavy AI spending with earnings growth, challenging market skepticism about the profitability of AI investments. Keyence (+30%), a newer portfolio addition, signaled a cyclical upturn in automotive and industrial markets, adding to the positive momentum.
Semiconductor Sector Rally Highlights Portfolio Positioning Risks
While AI themes boosted many tech stocks, Marlin’s underweight position in semiconductors weighed on returns. The iShares Semiconductor ETF soared 40%; its best monthly gain in 25 years; propelled by AI demand for chips from Intel (+114%), Micron (+53%), and SanDisk (+73%). This rapid rally reflects strong investor appetite for AI beneficiaries but also raises concerns about valuation risks given the sector’s historic boom-bust cycles.
Marlin prefers to gain AI exposure through hyper-scalers like Amazon and Alphabet, and key "picks-and-shovels" players such as ASML (+9%), Nvidia (+14%), and TSMC (+17%), rather than deeper semiconductor holdings. This cautious stance may shield the portfolio from volatility but also limits participation in the sector’s current surge.
Healthcare Stocks Face Sentiment Headwinds Despite Solid Fundamentals
The healthcare segment underperformed amid a rotation out of defensive sectors, despite underlying resilience. Procedure volumes remain robust, and capital spending on robotics and innovative treatments continues, as seen in Edwards Lifesciences (+4%) and Intuitive Surgical (-1%). Boston Scientific (-8%) and Danaher (-6%) face short-term challenges but maintain strong pipelines and market positions.
Investor skepticism about slowing medical device growth contrasts with the sector’s fundamentals, compressing valuations to near 30-year lows relative to the broader market. Marlin has trimmed healthcare exposure but retains conviction in high-quality companies benefiting from long-term innovation trends.
Other Portfolio Highlights and Market Environment
Floor & Décor (-5%) and Mastercard (+1%) experienced temporary headwinds linked to geopolitical tensions and consumer confidence, viewed by Marlin as cyclical rather than structural issues. Tencent (-3%) underperformed amid macroeconomic weakness and AI investment margin pressures but remains a compelling long-term AI play with valuations near two-decade lows.
No portfolio changes occurred in April, reflecting a steady hand amid market volatility. The fund’s sector allocation remains technology (23%), healthcare (20%), and consumer discretionary (19%), with geographic exposure heavily weighted to North America (78%).
April’s market backdrop featured record global equity highs despite geopolitical strains driving oil prices above $115 per barrel. Strong US earnings, particularly in tech, and a rally in emerging markets like South Korea’s KOSPI (+31%) underscored AI’s growing influence on market leadership.
Bottom Line?
Marlin’s preference for AI exposure through tech giants over semiconductors offers a defensive tilt but may cap upside if the chip rally endures.
Questions in the middle?
- Will semiconductor valuations sustain after a historic 40% monthly surge?
- Can healthcare stocks rebound as investor sentiment catches up with fundamentals?
- How will Marlin’s warrant issuance and capital management impact shareholder value over the next year?